ストックスクリーナーアプリを入手
33.23
2.50%
0.81
プレマーケット:
33.23
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0% - MarketBeat
Alpha Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision (NASDAQ:AGIO) - Seeking Alpha
Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - Insider Monkey
Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 - MSN
Agios Pharma Sets Milestones for Rare Disease Growth - TipRanks
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - The Manila Times
Agios' PYRUKYND Gets FDA Review for Thalassemia Treatment, Major Pipeline Progress for 2025 - StockTitan
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Agios' supplemental new drug application for its thalassemia treatment gets FDA nod - MSN
Agios Pharmaceuticals (AGIO-Q) QuotePress Release - The Globe and Mail
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5%Should You Sell? - MarketBeat
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND By Investing.com - Investing.com South Africa
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer – Company Announcement - Financial Times
FDA accepts Agios' sNDA for thalassemia treatment PYRUKYND - Investing.com India
FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia - The Manila Times
FDA Accepts Agios' PYRUKYND® Application for Thalassemia Treatment Expansion - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 2,804 Shares - MarketBeat
Agios Pharmaceuticals executive sells shares worth $90,232 By Investing.com - Investing.com Canada
Agios Pharmaceuticals executive sells shares worth $90,232 - Investing.com
FDA liver injury warning label for Agios' Pyrukynd - The Pharma Letter
FDA approves label update for Agios's PYRUKYND By Investing.com - Investing.com Australia
Agios Pharmaceuticals (NASDAQ:AGIO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
FDA approves label update for Agios’s PYRUKYND By Investing.com - Investing.com Nigeria
FDA approves label update for Agios's PYRUKYND - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages - MarketBeat
JPMorgan Chase & Co. Sells 63,155 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December - MarketBeat
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Franklin Resources Inc. Buys Shares of 36,317 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Objective long/short (AGIO) Report - Stock Traders Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9%Should You Sell? - MarketBeat
Agios Pharmaceuticals' SWOT analysis: mitapivat potential drives stock outlook - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Agios gains EU orphan drug status for sickle cell treatment By Investing.com - Investing.com UK
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease - The Manila Times
Agios' Mitapivat Secures Coveted EU Orphan Drug Status for Sickle Cell Disease Treatment - StockTitan
Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 83 RS Rating - Investor's Business Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Trading 5.2% HigherStill a Buy? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
4.81%
大文字化:
|
ボリューム (24 時間):